Product Description: RMC-5127 is an orally active and brain-penetrant mutant-selective tri-complex RASG12V inhibitor. RMC-5127 non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding . RMC-5127 inhibits the RAS pathway in KRASG12V mutant cancer cells, reducing cell proliferation and inducing apoptosis. RMC-5127 is promising for research of cancers with RAS mutations, such as non-small cell lung cancer[1].
Applications: Cancer-Kinase/protease
Formula: C57H75N9O9S
References: [1]Chen Z, et al. RMC-5127, a first-in-class, orally bioavailable mutant-selective RASG12V (ON) inhibitor is central nervous system (CNS)-penetrant and demonstrates anti-tumor activity in a preclinical intracranial xenograft model[J]. Cancer Research, 2024, 84(6_Supplement): 3340-3340.
Molecular Weight: 1062.33
Research Area: Cancer
Target: Apoptosis;Ras
English
Deutsch
